Antibe Therapeutics Announces Addition to Its Board of Directors and Grant of Options

  Antibe Therapeutics Announces Addition to Its Board of Directors and Grant
  of Options

Business Wire

TORONTO -- May 12, 2014

Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV:ATE) is pleased
to announce the appointment of Samira Sakhia (B.Comm., MBA, CPA) to its Board
of Directors. Ms. Sakhia has been the CFO of Paladin Labs Inc. since 2002,
where she is responsible for leading the finance, operations, human resources,
and investor relations teams. Ms. Sakhia has been a key member of the
management team at Paladin and closely involved in the company’s strategy of
in-licensing, acquiring products, and acquiring other specialty pharmaceutical
companies in Canada and abroad. During her tenure, Paladin achieved remarkable
growth, increasing in value from $75 million to over $3 billion in 2014 when
it was acquired by Endo International plc. Prior to joining Paladin, Ms.
Sakhia held several leadership positions at Discreet Logic Inc. including
Controller of North American Operations, Manager of International Financial
Reporting (Montreal, Quebec), and European Financial Manager (London,
England). Prior to working at Discreet Logic, Ms. Sakhia worked as an auditor
at Arthur Andersen & Co. Ms. Sakhia holds a Bachelor of Commerce degree in
Finance and Accounting, and an MBA in Strategy and Marketing, all from McGill
University. In addition, Ms. Sakhia is a Canadian-designated Chartered
Professional Accountant. Ms. Sakhia was the recipient of the 2014 Aces of
Finance Award from the Quebec Chapter of the Financial Executive Institute of
Canada in the “Financial executive of a small or medium sized enterprise”

Walt Macnee, Antibe’s Chairman, said “We are delighted to add Ms. Sakhia to
the Antibe Board. Her pharmaceutical industry expertise and financial acumen
will be a tremendous asset to us as we grow.”

The Corporation has granted Ms. Sakhia as well as an existing member of its
management team options to purchase a total of 100,000 common shares of Antibe
pursuant to the Corporation’s stock option plan. Each option bears an exercise
price of $0.54, being the closing price of Antibe shares on May 9, 2014, and
an expiry date of May 9, 2024. Twenty-five percent of the options vest on the
grant date and 1/36^th of the remaining options vest in each of the subsequent
36 months.

About Antibe Therapeutics Inc.

Antibe Therapeutics Inc. originates, develops and out-licenses
patent-protected new pharmaceuticals that areimproved versions of existing
drugs. These improvements are based on Nobel Prize-winning medical
researchhighlighting the crucial role of gaseous mediators, chemical
substances produced in the human bodyto regulate a range of fundamental
cellular processes. The Corporation’s drug design approach involveschemically
linking an existing off-patent drug (“base drug”) to an Antibe-patented,
hydrogen sulfide-releasingmolecule. For medical conditions characterized by
inflammation, pain or vascular dysfunction, this design approach can
efficiently produce improved versions of a number of existing drugs. Notably,
Antibe’sproducts are themselves fully patent-protectable and may benefit from
the predictable toxicity and effectivenessprofiles of the base drug.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that
term is defined in the policies ofthe TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.


Antibe Therapeutics Inc.
Dan Legault, 416-473-4095
Chief Executive Officer
Press spacebar to pause and continue. Press esc to stop.